Neurocrine appoints Andrew Ratz as senior VP

24 January 2025

Neurocrine Biosciences (Nasdaq: NBIX) has announced the appointment of Andrew Ratz as senior VP of drug development, supporting the firm’s expanding R&D efforts.

Dr Ratz brings nearly three decades of experience from Eli Lilly (NYSE: LLY), where he led initiatives spanning drug delivery, device development, and chemical engineering, contributing to over 25 product approvals.

Chief scientific officer Jude Onyia said: “Andy brings unparalleled leadership and experience to Neurocrine's R&D team,” adding: “He joins at a critical and exciting time as we strive to discover and develop the next generation of treatments for patients with great needs.”

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical